Seeking Alpha

Eli Lilly (LLY), which is suffering from a massive patent cliff and faces another one in 2017,...

Eli Lilly (LLY), which is suffering from a massive patent cliff and faces another one in 2017, could keep marketing exclusivity for its blockbuster Alimta lung cancer drug until 2022 rather than 2016 if it wins a case over a "method-of-use" patent on the way the multibillion dollar selling treatment is administered. Such IP is usually not upheld, although some experts believe that the Alimta case is different. Generic firms such as Teva (TEVA) argue otherwise.
From other sites
Comments (3)
  • doc47
    , contributor
    Comments (1410) | Send Message
     
    Teva needs to win one soon, otherwise all the bulls on the stock that appear here regularly will need to pull another rabbit out of their collective "undervalued" hat to tout the stock like they did when it was in the mid to low 40s.
    4 Jan 2013, 08:29 AM Reply Like
  • tampabay
    , contributor
    Comments (352) | Send Message
     
    Been hearing nothing but Patient Cliffs for LLY for year(s) and all I do is make money....should I jump off a cliff or should some of the distractors?
    4 Jan 2013, 11:04 AM Reply Like
  • raschulman
    , contributor
    Comments (3) | Send Message
     
    Two years ago, you guys should've told us about Watson.
    28 Jan 2013, 11:09 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs